Targeting proteinase-activated receptors: therapeutic potential and challenges
- PMID: 22212680
- DOI: 10.1038/nrd3615
Targeting proteinase-activated receptors: therapeutic potential and challenges
Abstract
Proteinase-activated receptors (PARs), a family of four seven-transmembrane G protein-coupled receptors, act as targets for signalling by various proteolytic enzymes. PARs are characterized by a unique activation mechanism involving the proteolytic unmasking of a tethered ligand that stimulates the receptor. Given the emerging roles of these receptors in cancer as well as in disorders of the cardiovascular, musculoskeletal, gastrointestinal, respiratory and central nervous system, PARs have become attractive targets for the development of novel therapeutics. In this Review we summarize the mechanisms by which PARs modulate cell function and the roles they can have in physiology and diseases. Furthermore, we provide an overview of possible strategies for developing PAR antagonists.
Similar articles
-
[Development of agonists/antagonists for protease-activated receptors (PARs) and the possible therapeutic application to gastrointestinal diseases].Yakugaku Zasshi. 2005 Jun;125(6):491-8. doi: 10.1248/yakushi.125.491. Yakugaku Zasshi. 2005. PMID: 15930817 Review. Japanese.
-
Challenges and Opportunities in Protease-Activated Receptor Drug Development.Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:349-373. doi: 10.1146/annurev-pharmtox-011613-140016. Epub 2016 Sep 9. Annu Rev Pharmacol Toxicol. 2017. PMID: 27618736 Review.
-
Proteinases, proteinase-activated receptors (PARs) and the pathophysiology of cancer and diseases of the cardiovascular, musculoskeletal, nervous and gastrointestinal systems.Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):377-92. doi: 10.1007/s00210-007-0194-2. Epub 2007 Oct 19. Naunyn Schmiedebergs Arch Pharmacol. 2008. PMID: 17952408 Review.
-
Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease.Br J Pharmacol. 2014 Mar;171(5):1180-94. doi: 10.1111/bph.12544. Br J Pharmacol. 2014. PMID: 24354792 Free PMC article. Review.
-
Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer.Biol Chem. 2008 Jun;389(6):643-51. doi: 10.1515/BC.2008.077. Biol Chem. 2008. PMID: 18627296 Review.
Cited by
-
PAR-4/Ca2+-calpain pathway activation stimulates platelet-derived microparticles in hyperglycemic type 2 diabetes.Cardiovasc Diabetol. 2021 Apr 3;20(1):77. doi: 10.1186/s12933-021-01267-w. Cardiovasc Diabetol. 2021. PMID: 33812377 Free PMC article.
-
Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?Int J Mol Sci. 2019 Nov 11;20(22):5629. doi: 10.3390/ijms20225629. Int J Mol Sci. 2019. PMID: 31717963 Free PMC article. Review.
-
Cathepsin S signals via PAR2 and generates a novel tethered ligand receptor agonist.PLoS One. 2014 Jun 25;9(6):e99702. doi: 10.1371/journal.pone.0099702. eCollection 2014. PLoS One. 2014. PMID: 24964046 Free PMC article.
-
The characteristics of thrombin in osteoarthritic pathogenesis and treatment.Biomed Res Int. 2014;2014:407518. doi: 10.1155/2014/407518. Epub 2014 Sep 16. Biomed Res Int. 2014. PMID: 25313362 Free PMC article. Review.
-
Antagonism of Protease Activated Receptor-2 by GB88 Reduces Inflammation Triggered by Protease Allergen Tyr-p3.Front Immunol. 2021 Sep 8;12:557433. doi: 10.3389/fimmu.2021.557433. eCollection 2021. Front Immunol. 2021. PMID: 34566947 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous